Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.73 |
| ▸ | MAPT | P10636 | 2/20 | 0.73 |
| ▸ | TERT | O14746 | 1/20 | 0.73 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TTR | P02766 | 1/20 | 0.64 |
| ▸ | MMP1 | P03956 | 1/20 | 0.64 |
| ▸ | APP | P05067 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CA3 | P07451 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8847713 | 0.90 | SNCA (0.78) | SNCAMAPTTERTCXCL12KDM4E | |
| SCHEMBL8847715 | 0.90 | SNCA (0.78) | SNCAMAPTTERTCXCL12KDM4E | |
| SCHEMBL4969360 | 0.85 | SNCA (0.75) | SNCAMAPTTERTCXCL12MEN1 | |
| SCHEMBL28094314 | 0.85 | SNCA (0.81) | SNCAMAPTTERTCXCL12KDM4E | |
| SCHEMBL4972250 | 0.85 | MAPT (0.75) | SNCAMAPTTERTCXCL12KDM4E | |
| SCHEMBL25214104 | 0.85 | MAPT (0.75) | SNCAMAPTTERTCXCL12KDM4E | |
| SCHEMBL5519499 | 0.85 | SNCA (0.75) | SNCAMAPTTERTCXCL12MEN1 | |
| SCHEMBL30384507 | 0.85 | MAPT (0.75) | SNCAMAPTTERTCXCL12KDM4E | |
| SCHEMBL30569484 | 0.85 | MAPT (0.75) | SNCAMAPTTERTCXCL12KDM4E | |
| SCHEMBL1878031 | 0.85 | MAPT (0.75) | SNCAMAPTTERTCXCL12KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050049242-A1 | Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049242-A1 | Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors | DDO, DNTT, DSTYK | SNCA 3025/4885MAPT 2039/4885TERT 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.